CRISPR Therapeutics AG Stock News

Corporate insiders have taken a sharply pessimistic turn – selling their companies' shares at the fastest rate in at least a decade.

Where can you find the next monster stocks? Check out the biotech space.

How long do you plan on sticking with a stock when you buy it? If you're a believer in Warren Buffett's proven approach, then your favorite holding period is forever.

Curing disease, as opposed to just masking symptoms, is a big deal. CRISPR Therapeutics aims to cure by editing problem genes. So CRSP is the future of medicine! This approach can be too futuristic for many tastes. That, plus questions about CRSP's ability to scale production and make treatments affordable, have been like a cloud over the stock. But in June, CRSP picked up some big-time express...

When picking new stocks for your portfolio, your best bet is looking for companies that you can hold forever. It may take that long for an idea or a business premise to fully pay off!

There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues that predate this year. Take, for instance, CRISPR Therapeutics (CRSP 6.43%) and Viking Therapeutics (VKTX 3.94%), two mid-cap biotech companies that have lagged broader equities over the trailing-12-month period.

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least.

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile-